Literature DB >> 1832357

The role of insulin insensitivity and hepatic lipase in the dyslipidaemia of type 2 diabetes.

C Baynes1, A D Henderson, V Anyaoku, W Richmond, C L Hughes, D G Johnston, R S Elkeles.   

Abstract

Fourteen male patients with Type 2 diabetes were studied to identify relationships between insulin-mediated glucose disposal, basal and glucose-stimulated insulin secretion, fasting lipoproteins and apolipoproteins, and the activities of lipoprotein lipase and hepatic lipase. Sensitivity of glucose disposal to exogenous insulin correlated positively with HDL-cholesterol (r = 0.65, p less than 0.05), HDL2-cholesterol (r = 0.59, p less than 0.05), and apolipoprotein A1 (r = 0.57, p less than 0.05) and negatively with apolipoprotein B (r = -0.53, p less than 0.05) and total: HDL-cholesterol ratio (r = -0.68, p less than 0.01). Fasting C-peptide correlated negatively with HDL-cholesterol (r = -0.76, p less than 0.01), HDL2-cholesterol (r = -0.80, p less than 0.001) and apoprotein A1 (r = -0.56, p less than 0.05) and positively with total: HDL-cholesterol ratio (r = 0.64, p less than 0.05). Neither fasting plasma glucose nor the indices of stimulated insulin secretion (glucose-stimulated plasma insulin and C-peptide) were related to any of the lipoprotein measures. Insulin insensitivity and hyperinsulinaemia were both associated with higher levels of hepatic lipase activity but did not influence lipoprotein lipase activity. In multiple linear regression analysis, hepatic lipase activity was related to HDL-cholesterol independent of insulin insensitivity. In addition, fasting C-peptide alone accounted for 70% of the variance in hepatic lipase activity and this was independent of insulin sensitivity and body mass index. We propose that the abnormalities of HDL-cholesterol in Type 2 diabetes are closely related to enhanced hepatic lipase activity brought about by increased insulin secretion which, in turn, is secondary to the defect in insulin action.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1832357     DOI: 10.1111/j.1464-5491.1991.tb01652.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  14 in total

Review 1.  Mechanisms, significance and treatment of vascular dysfunction in type 2 diabetes mellitus: focus on lipid-regulating therapy.

Authors:  Richard J Woodman; Gerard T Chew; Gerald F Watts
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  FoxO transcription factors are required for hepatic HDL cholesterol clearance.

Authors:  Samuel X Lee; Markus Heine; Christian Schlein; Rajasekhar Ramakrishnan; Jing Liu; Gabriella Belnavis; Ido Haimi; Alexander W Fischer; Henry N Ginsberg; Joerg Heeren; Franz Rinninger; Rebecca A Haeusler
Journal:  J Clin Invest       Date:  2018-03-19       Impact factor: 14.808

Review 3.  HDL dysfunction in diabetes: causes and possible treatments.

Authors:  Dan Farbstein; Andrew P Levy
Journal:  Expert Rev Cardiovasc Ther       Date:  2012-03

Review 4.  Pathogenesis of Lipid Disorders in Insulin Resistance: a Brief Review.

Authors:  Petter Bjornstad; Robert H Eckel
Journal:  Curr Diab Rep       Date:  2018-10-17       Impact factor: 4.810

5.  Changes of lipolytic enzymes cluster with insulin resistance syndrome. Botnia Study Group.

Authors:  P Knudsen; J Eriksson; S Lahdenperä; J Kahri; L Groop; M R Taskinen
Journal:  Diabetologia       Date:  1995-03       Impact factor: 10.122

6.  Insulin resistance and abnormal albumin excretion in non-diabetic first-degree relatives of patients with NIDDM.

Authors:  C M Forsblom; J G Eriksson; A V Ekstrand; A M Teppo; M R Taskinen; L C Groop
Journal:  Diabetologia       Date:  1995-03       Impact factor: 10.122

7.  Mouse hepatic lipase alleles with variable effects on lipoprotein composition and size.

Authors:  Serena M Pratt; Sally Chiu; Glenda M Espinal; Noreene M Shibata; Howard Wong; Craig H Warden
Journal:  J Lipid Res       Date:  2009-11-05       Impact factor: 5.922

Review 8.  Diabetic dyslipidaemia: from basic research to clinical practice.

Authors:  M-R Taskinen
Journal:  Diabetologia       Date:  2003-05-28       Impact factor: 10.122

9.  Lipoprotein kinetics in the metabolic syndrome: pathophysiological and therapeutic lessons from stable isotope studies.

Authors:  Dick C Chan; P Hugh R Barrett; Gerald F Watts
Journal:  Clin Biochem Rev       Date:  2004-02

10.  When HDL gets fat...

Authors:  Robert J Brown; Daniel J Rader
Journal:  Circ Res       Date:  2008-07-18       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.